- Correction
- Open access
- Published:
Correction: Treating posttraumatic stress disorder in substance use disorder patients with co-occurring posttraumatic stress disorder: study protocol for a randomized controlled trial to compare the effectiveness of different types and timings of treatment
BMC Psychiatry volume 22, Article number: 482 (2022)
The Original Article was published on 07 September 2021
Correction: BMC Psychiatry 21, 442 (2021)
https://doi.org/10.1186/s12888-021-03366-0
Following publication of the original article [1], the authors would like to correct the text under the heading Sample size. The updated text is given below.
Sample size
First, the required sample size was calculated to explore differential effectiveness between active PTSD treatments in reducing PTSD symptoms, regardless of timing of PTSD treatment. Three pairwise comparisons will be conducted between the active treatment arms (ImRs vs. PE, ImRs vs. EMDR; PE vs. EMDR). Due to the exploratory nature of this objective, an alpha of 0.05 and power of 0.80 are acceptable. Patients in the SUD treatment only condition will be randomly allocated to PE, EMDR or ImRs after SUD treatment and therefore are included in comparisons of the active treatment arms. To detect a medium effect size (d=0.50) in a pairwise comparison between two active treatment arms, with alpha=0.05, power=0.80 and within-person correlation coefficient=0.60, 52 participants are needed per arm. To make three pairwise comparisons 3 * 52 = 156 participants are needed for this comparison.
Second, the required sample size was calculated to compare the timings of PTSD-treatment (simultaneous vs. sequential), regardless of type of PTSD-treatment. The allocation ratio between sequential and simultaneous PTSD treatment is 1:3. To be able to detect a medium effect size (d=0.45) in a comparison between two arms, with an alpha=0.05, power=0.80 and within-person correlation coefficient=0.60, 41 participants are needed in the sequential arm and 123 participants are needed in the simultaneous arm. In total, 41 + 123 = 164 participants are needed for this comparison. Finally, we expect 20% of the participants to drop out of the study, therefore in total 205 participants will be included in the study.
The original article [1] has been corrected.
Reference
Lortye, et al. Treating posttraumatic stress disorder in substance use disorder patients with co-occurring posttraumatic stress disorder: study protocol for a randomized controlled trial to compare the effectiveness of different types and timings of treatment. BMC Psychiatry. 2021;21:442. https://doi.org/10.1186/s12888-021-03366-0.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
About this article
Cite this article
Lortye, S.A., Will, J.P., Marquenie, L.A. et al. Correction: Treating posttraumatic stress disorder in substance use disorder patients with co-occurring posttraumatic stress disorder: study protocol for a randomized controlled trial to compare the effectiveness of different types and timings of treatment. BMC Psychiatry 22, 482 (2022). https://doi.org/10.1186/s12888-022-04092-x
Published:
DOI: https://doi.org/10.1186/s12888-022-04092-x